Vaccine and blood products maker CSL has reportedly agreed to settle a major price-fixing class action against the company with a $60 million offer that, if cleared, would end a four-year case initiated by various healthcare groups.
According to reports, US- and Puerto Rico-based health groups involving private hospitals first sued CSL in 2009 accusing the company and others of fixing treatment prices for plasma therapy by colluding to restrict supplies.
CSL continues to deny the allegations, but in a statement said the negotiated settlement was in the best interest of the firm and its shareholders.
Reports say the lawsuit was launched following the US Federal Trade Commission’s blockage of CSL’s attempted takeover of rival Talecris Therapeutics for $3.1 billion, finding the competitors operated as a “tight oligopoly” and manipulated markets.
Full Content: Herald Sun
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI